Vasodilators in acute heart failure - evidence based on new studies

European Journal of Internal Medicine
André M Travessa, L Menezes Falcão

Abstract

Acute heart failure (AHF) contributes largely to the worldwide burden of heart failure (HF) and is associated with high mortality, poor prognosis and high rehospitalization rate. The pharmacologic therapy of AHF includes diuretics and vasodilators, which are a keystone when fluid overload and congestion are present. However, vasodilators are mainly focused on controlling symptoms, and drugs that also improve long-term mortality and morbidity seem to be in high demand. In this review, we summarize the existing evidence on mortality benefits of IV vasodilators in AHF. There is lack of evidence on the mortality benefits of IV vasodilators in AHF, as well as well-designed and large-scale trials for some of them. The existing trials on nitrates have conflicting results and are insufficient to establish definitive conclusions. Other vasodilators, such as enalaprilat, clevidipine, carperitide, and ularitide, have been evaluated only in a few trials assessing mortality. Levosimendan, nesititide and carperitide are approved by some regulatory agencies; however, data regarding mortality are also conflicting and large-scale post-marketing studies would be important. Serelaxin is a recent therapy with a novel mechanism of action and seemed...Continue Reading

Citations

Jan 3, 2020·Journal of Cardiovascular Pharmacology·Kazuo Yamagata
May 31, 2019·International Journal of Molecular Sciences·Daniela Maria TanaseMariana Floria

❮ Previous
Next ❯

Related Concepts

Related Feeds

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.

Related Papers

Progress in Cardiovascular Diseases
Ruth Hsiao, Barry H Greenberg
Heart Failure Reviews
John T ParissisMarkku Nieminen
Journal of Pharmacy Practice
Sarah Hanigan, Robert J DiDomenico
© 2022 Meta ULC. All rights reserved